Literature DB >> 12413565

MR-velocity mapping in vascular stents to assess peak systolic velocity. In vitro comparison of various stent designs made of Stainless Steel and Nitinol.

Jacqueline van Holten1, Patrik Kunz, Paul G H Mulder, Peter M T Pattynama, Hildo J Lamb, Lukas C van Dijk.   

Abstract

INTRODUCTION: Peak systolic velocity (PSV) measurements of blood flow inside vascular stents allow reliable detection of in-stent re-stenosis. The purpose of this in vitro study was to evaluate the feasibility of obtaining PSV measurements inside vascular stents made of Stainless Steel and Nitinol, using a velocity encoded MR technique. MATERIALS/
METHODS: In a flow phantom, stents of Stainless Steel and Nitinol were studied. The phantom was integrated into a closed-tubing circuit driven by a MR dedicated pulsatile flow pump. MR imaging was performed on a 1.5 T system. The PSV in the tube without stent was used as the gold standard to determine the accuracy and the variability (paired t-test and Pittman's test) of the PSV measurements inside the stents.
RESULTS: PSV values inside the stents showed percentual difference in mean of -15 to 21% (P < 0.05) at a pump setting of 10 and 20 ml/s.
CONCLUSION: PSV measurements can be accurately obtained inside stents made of Stainless Steel and Nitinol. MR-velocity measurements may be used in patients to non-invasively evaluate stent patency and in-stent re-stenosis. Copyright 2002 Elsevier Science B.V.

Entities:  

Mesh:

Substances:

Year:  2002        PMID: 12413565     DOI: 10.1007/bf02693844

Source DB:  PubMed          Journal:  MAGMA        ISSN: 0968-5243            Impact factor:   2.310


  24 in total

1.  Longitudinal straightening effect of stents is an additional predictor for major adverse cardiac events. Austrian Wiktor Stent Study Group and European Paragon Stent Investigators.

Authors:  M Gyöngyösi; P Yang; A Khorsand; D Glogar
Journal:  J Am Coll Cardiol       Date:  2000-05       Impact factor: 24.094

2.  Time-resolved contrast-enhanced MR angiography of renal artery stenosis: diagnostic accuracy and interobserver variability.

Authors:  M Völk; M Strotzer; M Lenhart; C Manke; W R Nitz; J Seitz; S Feuerbach; J Link
Journal:  AJR Am J Roentgenol       Date:  2000-06       Impact factor: 3.959

3.  A synergistic approach to optimal stenting: directional coronary atherectomy prior to coronary artery stent implantation--the AtheroLink Registry. AtheroLink Study Group.

Authors:  H W Höpp; F M Baer; C Ozbek; K H Kuck; B Scheller
Journal:  J Am Coll Cardiol       Date:  2000-11-15       Impact factor: 24.094

4.  Stent appearance at contrast-enhanced MR angiography: in vitro examination with 14 stents.

Authors:  M Lenhart; M Völk; C Manke; W R Nitz; M Strotzer; S Feuerbach; J Link
Journal:  Radiology       Date:  2000-10       Impact factor: 11.105

5.  Plain and covered stent-grafts: in vitro evaluation of characteristics at three-dimensional MR angiography.

Authors:  P R Hilfiker; H H Quick; J F Debatin
Journal:  Radiology       Date:  1999-06       Impact factor: 11.105

6.  Flow quantitation with echo-planar phase-contrast velocity mapping: in vitro and in vivo evaluation.

Authors:  J F Debatin; D A Leung; S Wildermuth; R Botnar; J Felblinger; G C McKinnon
Journal:  J Magn Reson Imaging       Date:  1995 Nov-Dec       Impact factor: 4.813

7.  Immediate stenting of iliofemoral occlusive lesions: a surgeon's early experiences.

Authors:  S W Cheng; A C Ting; H Lau; J Wong
Journal:  J Endovasc Surg       Date:  1999-08

8.  Patients with pulmonary fibrosis: cardiac function assessed with MR imaging.

Authors:  L J Kroft; P Simons; J M van Laar; A de Roos
Journal:  Radiology       Date:  2000-08       Impact factor: 11.105

9.  The Use of Vascular Stents in the Treatment of Iliac Artery Occlusion.

Authors: 
Journal:  Int J Angiol       Date:  2000-10

10.  MR imaging of vascular stents: effects of susceptibility, flow, and radiofrequency eddy currents.

Authors:  L W Bartels; H F Smits; C J Bakker; M A Viergever
Journal:  J Vasc Interv Radiol       Date:  2001-03       Impact factor: 3.464

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.